December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
What a Ph.D. student needs to know about Cancer Immunology and Immunotherapy – CCIT-DK
Nov 19, 2024, 20:50

What a Ph.D. student needs to know about Cancer Immunology and Immunotherapy – CCIT-DK

CCIT-DK – National Center for Cancer Immune Therapy of Denmark shared a post on LinkedIn:

“What a Ph.D. student needs to know about Cancer Immunology and Immunotherapy, all in one course. Register now to secure your spot!

What: PhD course ‘Cancer Immunology and Immunotherapy’, 4th edition.

Course Description.

When: 07/04-2025 (Monday) to – 11/04/2025 (Friday)

Where: Herlev, Denmark (Herlev Medborgerhus and Herlev Hospital)

Registration link.

Full program available soon!

The course is organized by CCIT-DK – National Center for Cancer Immune Therapy of Denmark (course director: Marco Donia), on behalf of the University of Copenhagen (Københavns Universitet).

If you are a PhD student at any University in Denmark, you can register free of charge. All other categories can register for a fee. Contact us (course secretary Mette Wassard Yde or Marco Donia) if you need more information.”

Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital. shared this post adding:

“Still two months left for registration, but we have only the last 11 available seats! Register now to ensure to secure your spot.”

What a Ph.D. student needs to know about Cancer Immunology and Immunotherapy - CCIT-DK

More posts featuring Marco Donia.

Marco Donia is a Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark.

He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen. Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1 resistant tumors.